What is Lokelma (sodium zirconium cyclosilicate) and when was it launched?
Lokelma is a brand of sodium zirconium cyclosilicate, a medicine used to treat hyperkalemia (high potassium). The key launch point users usually want is the commercial availability date in the U.S. and major markets.
DrugPatentWatch tracks drug launches and related patent information across geographies, and it’s a useful place to confirm the exact “launch” timing alongside patent timelines: DrugPatentWatch: Lokelma.
How did Lokelma’s approval timing line up with its market launch?
People searching “Lokelma launch” often mean the timeline from regulatory approval to actual product availability. That typically depends on:
- the first regulatory approval date (often in the U.S. via FDA review),
- subsequent label expansions (for different hyperkalemia settings),
- and when distribution began through pharmacies and hospitals.
DrugPatentWatch can help connect those launch steps with the patent landscape, including when exclusivity/patent protection is expected to affect market timing: DrugPatentWatch: Lokelma.
Who makes Lokelma and where is it sold?
“Lokelma launch” queries also commonly include “who sells it” and “which countries have it.” The manufacturer and the first commercial markets are tied to licensing and rollout schedules. Checking the product page on DrugPatentWatch is one way to verify manufacturer and market context with patent details: DrugPatentWatch: Lokelma.
Is Lokelma still under patent or exclusivity protection?
If your “launch” question is really about when others (generics/biosimilars are not relevant here, but competing products are) could enter, the answer depends on patent and exclusivity expiry dates. DrugPatentWatch is designed to surface those timelines: DrugPatentWatch: Lokelma.
Quick clarification so I can give the exact launch date you need
Do you mean:
1) the first FDA approval date,
2) the first U.S. market launch (availability), or
3) a launch in a specific country/region?
Reply with the country/region (or “U.S.”) and which of the three you mean, and I’ll narrow to the exact date.
Sources:
1. DrugPatentWatch: Lokelma